Education
About Us
Working with TipRanks
Follow Us
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
PMVP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.81 - $1.82
Previous CloseN/A
Volume81.53K
Average Volume (3M)277.12K
Market Cap
$72.73M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 07, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding51,952,680
10 Day Avg. Volume356,096
30 Day Avg. Volume277,116
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.00Price Target Upside1185.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment into the pivotal Ph2 portion of the PYNNACLE trial evaluating rezatapopt monotherapy in TP53 Y220C and KRAS WT advanced solid tumors remains on track.
Financial PerformancePMV ended 2024 with $183.3M in cash, which should fund operations to end-2026.
Regulatory PathwayManagement has indicated that approximately one-third of the trial's population will be ovarian cancer patients, potentially expediting approval.
Bears Say
Clinical RisksRisks include negative PC14586 clinical data, delays in moving candidates into advanced trials, and setbacks in later-stage studies.
Product Development ChallengesThere is a low probability of PC14586 monotherapy deployment in a tumor-agnostic fashion due to the minimum requirement criteria.
PMV Pharmaceuticals News
PMVP FAQ
What was PMV Pharmaceuticals’s price range in the past 12 months?
PMV Pharmaceuticals lowest stock price was $0.81 and its highest was $1.82 in the past 12 months.
What is PMV Pharmaceuticals’s market cap?
PMV Pharmaceuticals’s market cap is $72.73M.
When is PMV Pharmaceuticals’s upcoming earnings report date?
PMV Pharmaceuticals’s upcoming earnings report date is Aug 07, 2025 which is in 4 days.
How were PMV Pharmaceuticals’s earnings last quarter?
PMV Pharmaceuticals released its earnings results on May 09, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.372 by $0.032.
Is PMV Pharmaceuticals overvalued?
According to Wall Street analysts PMV Pharmaceuticals’s price is currently Undervalued.
Does PMV Pharmaceuticals pay dividends?
PMV Pharmaceuticals does not currently pay dividends.
What is PMV Pharmaceuticals’s EPS estimate?
PMV Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does PMV Pharmaceuticals have?
PMV Pharmaceuticals has 51,952,680 shares outstanding.
What happened to PMV Pharmaceuticals’s price movement after its last earnings report?
PMV Pharmaceuticals reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.372. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PMV Pharmaceuticals?
Currently, no hedge funds are holding shares in PMVP
PMV Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (1185.71% Upside)
$18.00 (1185.71% Upside)
Hedge Fund Trend
Decreased
By 322.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $65.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.94%
12-Months-Change
Fundamentals
Return on Equity
-32.66%
Trailing 12-Months
Asset Growth
-27.98%
Trailing 12-Months
Company Description
PMV Pharmaceuticals
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
PMVP Stock 12 Month Forecast
Average Price Target
$18.00
▲(1185.71%Upside)
Technical Analysis
PDS Biotechnology
―
CytomX Therapeutics
―
Cue Biopharma
―
Sutro Biopharma
―
Fractyl Health, Inc.
―
Ownership Overview
3.01% Insiders
8.49% Mutual Funds
0.56% Other Institutional Investors
83.77% Public Companies and
Individual Investors